Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) in a Representative Iranian Population

Trial Profile

Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) in a Representative Iranian Population

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Edaravone (Primary) ; Riluzole
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Sep 2017 Planned End Date changed from 6 Mar 2019 to 16 Mar 2019.
    • 09 Sep 2017 Planned primary completion date changed from 6 Mar 2019 to 16 Mar 2019.
    • 09 Sep 2017 Planned initiation date changed from 6 Sep 2017 to 16 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top